Eisai Inc.
Eisai Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1941, Eisai has established itself as a leader in the development of innovative treatments, particularly in neurology and oncology. The company is renowned for its core products, including the Alzheimer's treatment Aricept and the anti-cancer agent Lenvima, both of which exemplify Eisai's commitment to addressing unmet medical needs. With a strong focus on research and development, Eisai has achieved significant milestones, including numerous FDA approvals and partnerships that enhance its market position. The company's dedication to patient-centric solutions and its unique approach to drug development underscore its reputation as a trusted name in healthcare, making Eisai Inc. a vital contributor to advancements in medical science.
DitchCarbon Score
How does Eisai Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai Inc.'s score of 41 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai Inc.'s reported carbon emissions
In 2020, Eisai Inc. reported total carbon emissions of approximately 506,330,000 kg CO2e. This figure includes Scope 1 emissions of about 81,573,000 kg CO2e, Scope 2 emissions of around 130,752,000 kg CO2e, and significant Scope 3 emissions totalling approximately 399,845,000 kg CO2e. The combined Scope 1 and 2 emissions amounted to about 212,325,000 kg CO2e. Eisai has not disclosed specific reduction targets or initiatives related to the Science Based Targets initiative (SBTi) or other climate pledges. The absence of defined reduction goals suggests a need for further commitment to climate action within the pharmaceutical industry context. As a company headquartered in the US, Eisai's emissions data highlights the importance of addressing carbon footprints and implementing effective strategies for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | |
|---|---|
| Scope 1 | 81,573,000 |
| Scope 2 | 130,752,000 |
| Scope 3 | 399,845,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
